当前位置: 首页 >> 检索结果
4681. Clinical study of the effects of latissimus dorsi muscle flap stimulation after cardiomyoplasty.
作者: A A Hagège.;M Desnos.;F Fernandez.;B Besse.;N Mirochnik.;M Castaldo.;J C Chachques.;A Carpentier.;C Guérot.
来源: Circulation. 1995年92卷9 Suppl期II210-5页
Beneficial hemodynamic effects after dynamic cardiomyoplasty have been inconsistently demonstrated, and the effects seen may be due to the wrap itself, to flap stimulation, or both. The aim of this study was to determine whether flap stimulation per se acts as a systolic active process after cardiomyoplasty.
4682. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure.
作者: K B James.;P M McCarthy.;J D Thomas.;R Vargo.;R E Hobbs.;S Sapp.;E Bravo.
来源: Circulation. 1995年92卷9 Suppl期II191-5页
The HeartMate left ventricular assist device has been successfully used as a bridge to cardiac transplantation. Because many patients exhibit marked clinical improvement in their heart failure after HeartMate implantation, we studied the physiological effect of this device on the neurohormonal axis.
4683. Early changes in regional and global left ventricular function after aortic valve replacement. Comparison of crystalloid, cold blood, and warm blood cardioplegias.
The clinical effects of different cardioplegic methods on left ventricular (LV) function have not been fully elucidated, particularly in the setting of myocardial hypertrophy.
4684. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Improvement of cardiac ischemia at 1 year after PTCA and CABG.
作者: M G Bourassa.;G L Knatterud.;C J Pepine.;G Sopko.;W J Rogers.;N L Geller.;I Dyrda.;S A Forman.;B R Chaitman.;B Sharaf.
来源: Circulation. 1995年92卷9 Suppl期II1-7页
Cardiac ischemia on the ambulatory ECG (AECG) and/or on the exercise treadmill test (ETT) is associated with an increased risk of adverse outcome. Myocardial revascularization more often suppresses cardiac ischemia than does medical management alone. However, few studies have compared the effects of percutaneous transluminal coronary angioplasty (PTCA) with those of coronary artery bypass grafting (CABG) on cardiac ischemia and clinical outcome.
4685. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass.
Extracorporeal circulation with circuits coated with surface-bound heparin has allowed reduced levels of systemic heparinization. Clinical benefits have included reduced postoperative bleeding and less homologous blood usage. However, the effects on the hemostatic and fibrinolytic systems have remained in part unknown.
4686. Primary ventricular fibrillation is associated with increased paced right ventricular electrogram fractionation.
作者: R C Saumarez.;S Heald.;J Gill.;A K Slade.;M de Belder.;F Walczak.;E Rowland.;D E Ward.;A J Camm.
来源: Circulation. 1995年92卷9期2565-71页
The mechanisms of spontaneous ventricular fibrillation (primary VF) in patients without structural heart disease are obscure. A new technique has shown that in patients with hypertrophic cardiomyopathy conduction of fractionated ventricular paced beats, recorded at several right ventricular sites, is prolonged in individuals who have suffered a VF arrest, and this may reveal one component of a reentrant substrate. Patients with primary VF were studied with the same methods to determine whether similar abnormalities are present in this group.
4687. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
来源: Circulation. 1995年92卷9期2550-7页
Few antiarrhythmic agents have been shown in randomized controlled trials to be effective and well tolerated in the prophylaxis of paroxysmal supraventricular tachycardia or paroxysmal atrial fibrillation. Propafenone, a class IC anti-arrhythmic agent with weak beta-adrenoceptor antagonist properties, has shown promise in preliminary clinical studies.
4688. Radionuclide monitoring of cardiac adaptations to volume loading in patients with dilated cardiomyopathy and mild heart failure. Effects of angiotensin-converting enzyme inhibition.
作者: M Volpe.;M A Rao.;A Cuocolo.;R Russo.;A Nappi.;A F Mele.;I Enea.;B Trimarco.;M Condorelli.
来源: Circulation. 1995年92卷9期2511-8页
Cardiac adaptations to volume overload have been poorly investigated in heart failure. The aim of this study was to assess dynamic left ventricular responses to acute volume loading by continuous radionuclide monitoring in patients with asymptomatic to mildly symptomatic left ventricular dysfunction.
4689. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators.
作者: D J Cohen.;H M Krumholz.;C A Sukin.;K K Ho.;R B Siegrist.;M Cleman.;R R Heuser.;J A Brinker.;J W Moses.;M P Savage.
来源: Circulation. 1995年92卷9期2480-7页
Coronary stenting has been shown to improve initial success, reduce angiographic restenosis, and reduce the need for repeat revascularization compared with conventional balloon angioplasty (PTCA). Although previous studies have demonstrated that initial hospital costs for stenting are considerably higher than those for conventional PTCA, the impact of coronary stenting on long-term medical care costs remains unknown.
4690. Intracoronary heparin delivery in humans. Acute feasibility and long-term results.
作者: E Camenzind.;P P Kint.;C Di Mario.;J Ligthart.;W van der Giessen.;E Boersma.;P W Serruys.
来源: Circulation. 1995年92卷9期2463-72页
Inefficacy of systemic drug administration for restenosis prevention may partially relate to insufficient local drug concentration. This study aimed to evaluate the acute feasibility and long-term outcome of using an infusion-perfusion coil balloon, Dispatch.
4691. Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina.
Whether focal vasospasticity plays a pathogenic role in the progression or regression of coronary atherosclerosis is unknown. To determine whether evidence for such a role exists, we studied long-term changes in coronary luminal measurements in patients with vasospastic angina.
4692. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group.
作者: J M Flack.;J Neaton.;R Grimm.;J Shih.;J Cutler.;K Ensrud.;S MacMahon.
来源: Circulation. 1995年92卷9期2437-45页
The purpose of the present study was to describe the relation between blood pressure (systolic [SBP] and diastolic [DBP]) and death from coronary heart disease (CHD) and all causes for men with a history of myocardial infarction (MI).
4693. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin.
Smoking is associated with an increased risk of myocardial infarction and sudden death. Platelet activation and thrombosis at sites of vessel stenosis and injury or plaque disruption play a crucial role in these acute coronary events. Thus, the aim of this study was to determine whether cigarette smoking acutely increases platelet thrombus formation on an injured arterial surface at local shear rates typical of a stenotic artery.
4694. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans.
作者: A Lerman.;D R Holmes.;M R Bell.;K N Garratt.;R A Nishimura.;J C Burnett.
来源: Circulation. 1995年92卷9期2426-31页
The endothelium modulates vascular tone through release of vasodilating substances, such as endothelium-derived relaxing factors, and vasoconstricting substances, such as endothelin. Endothelin concentrations are elevated in humans with atherosclerosis and in hypercholesterolemic pigs. Furthermore, the endothelium-dependent vasodilator acetylcholine increases endothelin in hypercholesterolemia in association with coronary vasoconstriction. The present study was designed to test the hypotheses that coronary endothelial dysfunction in humans is characterized by enhanced coronary and circulating endothelin and that the vasoconstriction associated with acetylcholine results in further release of coronary endothelin.
4695. Compensatory vascular changes of remote coronary segments in response to lesion progression as observed by sequential angiography from a controlled clinical trial.
作者: A M Shircore.;W J Mack.;R H Selzer.;P L Lee.;S P Azen.;P Alaupovic.;H N Hodis.
来源: Circulation. 1995年92卷9期2411-8页
Local coronary artery enlargement to compensate for atherosclerotic plaques preserves the vessel lumen. The extent to which coronary segments remote from progressing lesions enlarge is unknown. This is clinically relevant since compensatory enlargement may be important in determining whether clinical complications result from progression of coronary artery disease (CAD). Additionally, compensatory change has implications for quantitative coronary angiographic (QCA) trials, since the effect of progression on diameter means may be mitigated by compensatory changes in remote coronary segments when QCA change is averaged over all lesions.
4696. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.
作者: D Waters.;L Higginson.;P Gladstone.;S J Boccuzzi.;T Cook.;J Lespérance.
来源: Circulation. 1995年92卷9期2404-10页
Although coronary disease is the leading cause of death in women and its clinical features differ from those in men, very few women have been included in angiographic trials of cholesterol lowering.
4697. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.
作者: J H Levy.;R Pifarre.;H V Schaff.;J C Horrow.;R Albus.;B Spiess.;T K Rosengart.;J Murray.;R E Clark.;P Smith.
来源: Circulation. 1995年92卷8期2236-44页
Aprotinin is a serine protease inhibitor that reduces blood loss and transfusion requirements when administered prophylactically to cardiac surgical patients. To examine the safety and dose-related efficacy of aprotinin, a prospective, multicenter, placebo-controlled trial was conducted in patients undergoing repeat coronary artery bypass graft (CABG) surgery.
4698. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest.
作者: G Wernovsky.;D Wypij.;R A Jonas.;J E Mayer.;F L Hanley.;P R Hickey.;A Z Walsh.;A C Chang.;A R Castañeda.;J W Newburger.;D L Wessel.
来源: Circulation. 1995年92卷8期2226-35页
The neurological morbidity associated with prolonged periods of circulatory arrest has led some cardiac surgical teams to promote continuous low-flow cardiopulmonary bypass as an alternative strategy. The nonneurological postoperative effects of both techniques have been previously studied only in a limited fashion.
4699. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
作者: M D Ezekowitz.;K E James.;S M Nazarian.;J Davenport.;J P Broderick.;S R Gupta.;V Thadani.;M L Meyer.;S L Bridgers.
来源: Circulation. 1995年92卷8期2178-82页
Cerebral infarction in patients with atrial fibrillation may vary from being clinically silent to catastrophic. The prevalence of silent cerebral infarction and its effect as a risk factor for symptomatic stroke are important considerations for the evaluation of patients with atrial fibrillation.
4700. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
作者: S Vanderschueren.;L Barrios.;P Kerdsinchai.;P Van den Heuvel.;L Hermans.;M Vrolix.;F De Man.;E Benit.;L Muyldermans.;D Collen.
来源: Circulation. 1995年92卷8期2044-9页
Recombinant staphylokinase (STAR) was shown recently to offer promise for coronary arterial thrombolysis in patients with evolving myocardial infarction. The present multicenter randomized open trial was designed to assess the thrombolytic efficacy, safety, and fibrin specificity of STAR relative to accelerated alteplase (recombinant tissue-type plasminogen activator [RTPA]).
|